ARCA biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ARCA biopharma and buy or sell other stocks, ETFs, and their options commission-free!

About ABIO

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. 

CEO
Lawrence O. Klein, PhD
CEOLawrence O. Klein, PhD
Employees
28
Employees28
Headquarters
Menlo Park, California
HeadquartersMenlo Park, California
Founded
Founded
Employees
28
Employees28

ABIO Key Statistics

Market cap
119.44M
Market cap119.44M
Price-Earnings ratio
-1.91
Price-Earnings ratio-1.91
Dividend yield
Dividend yield
Average volume
123.31K
Average volume123.31K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$33.00
52 Week high$33.00
52 Week low
$5.49
52 Week low$5.49

Stock Snapshot

The current ARCA biopharma(ABIO) stock price is $3.19, with a market capitalization of 119.44M. The stock trades at a price-to-earnings (P/E) ratio of -1.91.

On 2026-05-12, ARCA biopharma(ABIO) stock opened at —, reached a high of —, and a low of —.

The ARCA biopharma(ABIO)'s current trading volume is 0, compared to an average daily volume of 123.31K.

During the past year, ARCA biopharma(ABIO) stock moved between $5.49 at its lowest and $33.00 at its peak.

During the past year, ARCA biopharma(ABIO) stock moved between $5.49 at its lowest and $33.00 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.